Moderna is a biotechnology company, not an exchange-traded fund, and it carries broad sell-side coverage. Yet the extraordinary 2026 rally has inverted the usual relationship between the stock price and analyst price targets. Recent aggregations place the average analyst price target near $138, with a spread spanning roughly $40 on the low end to about $170 on the high end. Even the most bullish published target — Bank of America's $170, set after the firm upgraded the stock to Neutral in August — sits roughly 23% below the recent market price.
Other recent targets include Goldman Sachs at $137 (Neutral), Morgan Stanley at $95, TD Cowen at $90 (Hold), and Citi at $80 with a Sell rating. Because no credible analyst target is above the current price, the minimum-distance rule for a meaningful upside objective cannot be satisfied with analyst data alone. The $250 figure used here therefore reflects public technical discussion — the round-number psychological level just beneath the stock's 52-week high of $254.48 — rather than any analyst consensus.
With shares near $221.72, a move to $250 represents roughly 13% upside — a modest advance that is effectively a retest of the stock's recent record high. That level is reachable in principle if the company's cancer-vaccine narrative continues to expand, but the path is not assured. The stock is highly volatile: it surged 177% in a single session in August after the intismeran melanoma readout, later pulled back more than 17% in a day, and still sits about 13% below its peak. Reaching $250 would require renewed conviction that the oncology pipeline can generate transformative revenue, not just positive trial headlines.
The central catalyst is intismeran, Moderna's personalized mRNA cancer vaccine used with Merck's Keytruda. Phase 3 data from the INTerpath-001 trial in resected melanoma showed the combination reduced recurrence and distant spread versus Keytruda alone, following five-year Phase 2b results showing a 49% reduction in risk of recurrence or death. Moderna is running nine Phase 2 and Phase 3 trials across melanoma, lung, bladder, and renal cell cancers. The August 2026 approval of mFLUSIVA, the first FDA-approved mRNA-based flu vaccine, and the company's addition to the Nasdaq 100 Index provide further narrative support. A favorable hazard-ratio disclosure at the ESMO conference could reinforce the bull case.
The principal obstacle is valuation. Citi, which downgraded the stock to Sell, argues that even assuming 100% success for the lead cancer programs, its net-present-value analysis supports only around $100 per share, and that justifying a $200-plus price would require roughly $26 billion in annual oncology sales. The company also remains deeply unprofitable, with quarterly revenue near $145 million and GAAP net losses in the hundreds of millions of dollars. Trial data so far lack effect sizes and mature survival curves, and melanoma may not validate the platform broadly across other tumor types. Any disappointing full data release, slower commercial uptake, or regulatory setback could trigger sharp multiple compression.
The dominant reference point is the 52-week high of $254.48, which acts as the key resistance zone; the $250 psychological level sits just beneath it. The stock's 52-week low of $22.28 underscores how far and how fast the shares have run. Between the current price and the target, there is little durable overhead supply, but the stock's extreme volatility means support is less established; round-number levels near $220 and $200 are the nearest zones to watch if momentum fades.
Analyst price targets generally reflect a research horizon of about 12 months, though individual firms differ. Key items to watch include the full Phase 3 intismeran data, upcoming earnings reports, any analyst target revisions, and regulatory milestones for the cancer and flu vaccines. Investors should also track cash position, quarterly losses, and whether Merck deepens or broadens the partnership, as these will shape whether the stock can reclaim its highs.
Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. For a fast-moving name like Moderna, these signals can help traders spot shifting trends, monitor positions, and discover new opportunities more efficiently than manual chart review. Traders seeking an automated edge can explore the platform to see how AI interprets the latest price action.
The question of whether Moderna can reach $250 is less about a distant valuation target and more about whether the shares can reclaim their recent record high. The objective, drawn from technical and psychological levels rather than analyst consensus, requires only a modest 13% advance. Support comes from a genuinely groundbreaking oncology pipeline, while the biggest obstacle is a valuation that has run far ahead of both analyst models and current financials, with the average analyst price target near $138 and the most bullish published target at $170. How the full trial data lands and whether the commercial story can catch up to the share price will determine the outcome.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, MRNA has been loosely correlated with BNTX. These tickers have moved in lockstep 60% of the time. This A.I.-generated data suggests there is some statistical probability that if MRNA jumps, then BNTX could also see price increases.
| Ticker / NAME | Correlation To MRNA | 1D Price Change % | ||
|---|---|---|---|---|
| MRNA | 100% | -2.17% | ||
| BNTX - MRNA | 60% Loosely correlated | -0.52% | ||
| CRSP - MRNA | 50% Loosely correlated | +0.44% | ||
| NVAX - MRNA | 48% Loosely correlated | -3.24% | ||
| ARCT - MRNA | 46% Loosely correlated | -1.97% | ||
| MRVI - MRNA | 45% Loosely correlated | -2.92% | ||
More | ||||